UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance

Molecular pharmaceutics, 2017-11, Vol.14 (11), p.3801-3814

2017

Volltextzugriff (PDF)

Evaluation of US Food and Drug Administration Drug Label Recommendations for Coadministration of Antivirals and Acid‐Reducing Agents

Clinical pharmacology and therapeutics, 2022-11, Vol.112 (5), p.1088-1097

2022

Volltextzugriff (PDF)

Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report

The AAPS journal, 2018-08, Vol.20 (6), p.93-93, Article 93

2018

Volltextzugriff (PDF)

Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse

Journal of clinical pharmacology, 2019-05, Vol.59 (5), p.625-637

2019

Volltextzugriff (PDF)

Industry Perspective on Standardizing Food-Effect Studies for New Drug Development

Clinical pharmacokinetics, 2018-08, Vol.57 (8), p.901-909

2018

Volltextzugriff (PDF)

History and Evolution of the Dissolution Test

Dissolution technologies, 2014-08, Vol.21 (3), p.11-16

Marroum, Patrick J.

2014

Volltextzugriff (PDF)

New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process

Journal of clinical pharmacology, 2008-06, Vol.48 (6), p.662-670

2008

Volltextzugriff (PDF)

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials

Clinical pharmacology in drug development, 2019-02, Vol.8 (2), p.208-216

2019

Volltextzugriff (PDF)

Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection

The AAPS journal, 2017-09, Vol.19 (5), p.1523-1535

2017

Volltextzugriff (PDF)

Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications

The AAPS journal, 2005-10, Vol.7 (3), p.E503-E512

2005

Volltextzugriff (PDF)

Developing Quantitative In Vitro–In Vivo Correlation for Fenofibrate Immediate-Release Formulations With the Biphasic Dissolution-Partition Test Method

Journal of pharmaceutical sciences, 2018-01, Vol.107 (1), p.476-487

2018

Volltextzugriff (PDF)

Role of In Vitro–In Vivo Correlations in Drug Development

Dissolution technologies, 2015-05, Vol.22 (2), p.50-56

Marroum, Patrick

2015

Volltextzugriff (PDF)

Venetoclax Clinical Pharmacokinetics After Administration of Crushed, Ground or Whole Tablets

Clinical therapeutics, 2024-05

2024

Volltextzugriff (PDF)

Virtual Bioequivalence Assessment of Elagolix Formulations Using Physiologically Based Pharmacokinetic Modeling

The AAPS journal, 2023-03, Vol.25 (3), p.30-30, Article 30

2023

Volltextzugriff (PDF)

Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making

Clinical pharmacokinetics, 2001, Vol.40 (12), p.883-892

2001

Volltextzugriff (PDF)

In Vivo Bioequivalence and In Vitro Similarity Factor (f2) for Dissolution Profile Comparisons of Extended Release Formulations: How and When Do They Match?

Pharmaceutical research, 2011-05, Vol.28 (5), p.1144-1156

2011

Volltextzugriff (PDF)

Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease

Clinical therapeutics, 2024-01, Vol.46 (1), p.30-39

2024

Volltextzugriff (PDF)

The product label: How pharmacokinetics and pharmacodynamics reach the prescriber

Clinical pharmacokinetics, 2002, Vol.41 (3), p.161-169

2002

Volltextzugriff (PDF)

Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure

Biopharmaceutics & drug disposition, 2022-06, Vol.43 (3), p.98-107

2022

Volltextzugriff (PDF)

Utility of Modeling and Simulation Approach to Support the Clinical Relevance of Dissolution Specifications: a Case Study from Upadacitinib Development

The AAPS journal, 2022-03, Vol.24 (2), p.39-39, Article 39

2022

Volltextzugriff (PDF)

Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data

Pharmaceutical research, 2017-07, Vol.34 (7), p.1527-1533

2017

Volltextzugriff (PDF)

Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation

The AAPS journal, 2019-11, Vol.21 (6), Article 108

2019

Volltextzugriff (PDF)

Analysis of level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability

Biopharmaceutics & drug disposition, 2013-07, Vol.34 (5), p.262-277

2013

Volltextzugriff (PDF)

Relationships between in vitro drug dissolution and in vivo response

Biopharmaceutics & drug disposition, 2012-10, Vol.33 (7), p.347-348

2012

Volltextzugriff (PDF)

Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet

Clinical drug investigation, 2022-08, Vol.42 (8), p.657-668

2022

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(29)

Publikationsform

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Pharmacology & Pharmacy
(30)
Humans
(21)
Pharmacokinetics
(10)
Pharmacology/toxicology
(9)
Biological And Medical Sciences
(8)
Dissolution
(8)
Medical Sciences
(8)
Biochemistry
(7)
Biological Availability
(7)
Biomedical And Life Sciences
(7)
Biomedicine
(7)
Pharmacology. Drug Treatments
(7)
Pharmacy
(7)
Therapeutic Equivalency
(7)
United States
(7)
United States Food And Drug Administration
(7)
Adult
(6)
Female
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance

Evaluation of US Food and Drug Administration Drug Label Recommendations for Coadministration of Antivirals and Acid‐Reducing Agents

Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report

Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse

Industry Perspective on Standardizing Food-Effect Studies for New Drug Development

History and Evolution of the Dissolution Test

New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials

Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection

Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications

Developing Quantitative In Vitro–In Vivo Correlation for Fenofibrate Immediate-Release Formulations With the Biphasic Dissolution-Partition Test Method

Role of In Vitro–In Vivo Correlations in Drug Development

Venetoclax Clinical Pharmacokinetics After Administration of Crushed, Ground or Whole Tablets

Virtual Bioequivalence Assessment of Elagolix Formulations Using Physiologically Based Pharmacokinetic Modeling

Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making

In Vivo Bioequivalence and In Vitro Similarity Factor (f2) for Dissolution Profile Comparisons of Extended Release Formulations: How and When Do They Match?

Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease

The product label: How pharmacokinetics and pharmacodynamics reach the prescriber

Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure

Utility of Modeling and Simulation Approach to Support the Clinical Relevance of Dissolution Specifications: a Case Study from Upadacitinib Development

Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data

Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation

Analysis of level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability

Relationships between in vitro drug dissolution and in vivo response

Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet

Suchergebnisse filtern